On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

Copy Space. Empty Space SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has approved the at-home use of the flu vaccine spray FluMist, how do you know ...

A variety of medical device innovations and diagnostics have been named by Time as some of the best inventions of 2024.

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Although getting a vaccine might be terrifying to some, staying up-to-date and getting them each year greatly decreases your risk of contracting and spreading diseases. But it’s important to ...

(Alliance News) - AstraZeneca PLC on Monday welcomed approval in the European Union of Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis. EGPA is a rare, immune-mediated ...

The approach, however, is far from perfect. For starters, 100,000 doses divided by 12 states isn’t a lot of vaccine. California, for instance, is the country’s largest milk producer ...

How big the wave ends up being depends in part on vaccine uptake. Last year, few people got the updated booster shot. If that’s the case again this year, we’re more likely to see widespread ...